EW Edwards Lifesciences

Q3 2025 10-Q

Filed: Nov 5, 2025Period ending Sep 30, 2025

Health Care

Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR

Edwards Lifesciences (EW) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $1.55B for Q3 2025, up 14.7% YoY from $1.35B; nine-month revenue $4.50B, up 11.0% YoY from $4.05B
• Gross profit rose YoY but gross margin declined due to forex and higher expenses; effective tax rate 16.1% vs 9.2% YoY for nine months

+3 more insights

Risk Factors

• No material changes to Risk Factors compared to 2024 10-K
• Continued exposure to product liability risks in medical device industry

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.6B

▲ +17.6% YoY▲ +1.4% QoQ

Net Income

$291M

▼ -90.5% YoY▼ -12.6% QoQ

Gross Margin

77.8%

▼ -378bp YoY▲ +25bp QoQ

Operating Margin

19.8%

▼ -641bp YoY▼ -706bp QoQ

Net Margin

18.7%

▼ -21373bp YoY▼ -300bp QoQ

ROE

2.9%

Total Assets

$13.3B

EPS (Diluted)

$0.49

▼ -90.4% YoY▼ -14.0% QoQ

Operating Cash Flow

$574M

▲ +63.1% YoY▲ +97.7% QoQ

Source: XBRL data from Edwards Lifesciences Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Edwards Lifesciences

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.